Carvolix

Carvolix EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Carvolix (CVX.PA) as of Oct 29, 2026 is -18.00 M EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -13.45 M EUR — a change of 33.81% (lower).

EBITDA

-18.00 MEUR

YoY

33.81%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Carvolix is 2025 -18.00 M EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Carvolix was 2024 -13.45 M EUR. It decreases by 33.81% lower compared to the previous year.

The Carvolix EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
-10.01 M EUR
Jan 1, 2019
-13.05 M EUR
Jan 1, 2020
-10.71 M EUR
Jan 1, 2021
-9.82 M EUR
Jan 1, 2022
-11.93 M EUR
Jan 1, 2023
-12.99 M EUR
Jan 1, 2024
-13.45 M EUR
Jan 1, 2025
-18.00 M EUR
The Carvolix EBITDA history
YEAREBITDAYoY
-18.00 MEUR+33.81%
-13.45 MEUR+3.56%
-12.99 MEUR+8.90%
-11.93 MEUR+21.51%
-9.82 MEUR-8.36%
-10.71 MEUR-17.94%
-13.05 MEUR+30.47%
-10.01 MEUR+46.29%
-6.84 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Carvolix Stock analysis

What does Carvolix do? Affluent Medical SA develops minimally invasive prostheses that mimic human anatomy and restore native physiology for cardiovascular and urological therapies. The company offers products including Kalios, Epygon, and Artus, targeting heart disease and urinary incontinence treatments. These solutions utilize transcatheter and flow control technologies with optimized, biocompatible components designed for minimally invasive implant procedures. The company's products are sold to healthcare providers and medical institutions seeking advanced solutions for critical conditions. Affluent Medical SA focuses on treating serious and widespread diseases through innovative implantable technologies that replicate natural bodily functions without extensive surgical intervention. With a workforce of 54 full-time employees based in Aix-En-Provence, Paca, the company delivers specialized medical devices that address unmet needs in cardiovascular and urological care. Its product portfolio targets high-value clinical segments where minimally invasive approaches improve patient outcomes and reduce recovery times. Carvolix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Carvolix stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Carvolix is -18.00 M EUR in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Carvolix changed from -13.45 M EUR to -18.00 M EUR, representing a 33.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Carvolix since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Carvolix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Carvolix

All Key Metrics — Carvolix